Last updated: September 15, 2026
Vorinostat, marketed as Zolinza by Merck, is an oral histone deacetylase inhibitor approved in the United States for cutaneous T-cell lymphoma (CTCL). Its commercial profile has shifted from branded orphan oncology product to mature generic medicine. Revenue potential is constrained by a narrow indication, competing CTCL therapies, chronic tolerability issues, and generic price erosion. The principal U.S. composition-of-matter patent protection has expired, and current competitive risk is commercial rather than primarily patent-based.
What is vorinostat and how is it used?
Vorinostat is a hydroxamic-acid histone deacetylase inhibitor that alters gene transcription and promotes differentiation or apoptosis in malignant cells. The FDA approved Zolinza on Oct. 6, 2006, for the treatment of progressive, persistent, or recurrent CTCL in patients who have received two systemic therapies [1].
The approved regimen is:
| Parameter |
FDA-approved information |
| Active ingredient |
Vorinostat |
| Brand |
Zolinza |
| Dosage form |
100 mg capsules |
| Standard dose |
400 mg orally once daily with food |
| Dose reduction |
300 mg once daily, or 300 mg once daily for five consecutive days each week, for toxicity |
| Initial U.S. indication |
CTCL after two systemic therapies |
| Sponsor at approval |
Merck & Co. |
| FDA approval date |
Oct. 6, 2006 |
| Regulatory classification |
Small-molecule oncology drug |
| Biosimilar pathway |
Not applicable |
Vorinostat is not approved in the United States for diffuse large B-cell lymphoma, multiple myeloma, acute myeloid leukemia, or other hematologic malignancies, despite investigation in those diseases.
What is the FDA and Orange Book status of Zolinza?
Zolinza is an FDA-approved small-molecule drug with generic competition. It is not a biologic and has no biosimilar market. Generic manufacturers file abbreviated new drug applications under the ANDA pathway.
The FDA-approved label identifies CTCL as the commercial indication. The Orange Book has historically listed patents associated with Zolinza and its active ingredient. The core U.S. patent estate has reached the end of its effective life, allowing generic manufacturers to compete once regulatory and patent requirements were satisfied [2].
| Regulatory issue |
Status |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Expired |
| Pediatric exclusivity |
Expired, if applicable |
| Core U.S. patent protection |
Expired |
| Orange Book relevance |
Historical listed patents; no durable current barrier to ANDA competition |
| Generic pathway |
ANDA |
| Biosimilar pathway |
Not applicable |
Vorinostat received seven years of orphan-drug exclusivity for the CTCL indication. Because the product was approved in 2006, that exclusivity period ended in 2013, subject to the scope of the approved indication and any applicable regulatory extensions [1, 3].
When did vorinostat lose exclusivity?
Vorinostat lost meaningful U.S. exclusivity in stages.
| Exclusivity event |
Approximate timing |
Commercial effect |
| FDA approval |
October 2006 |
Branded U.S. launch |
| Five-year new chemical entity exclusivity |
October 2011 |
Delayed certain ANDA approvals |
| Seven-year orphan exclusivity |
October 2013 |
Protected the approved CTCL indication |
| Core patent term |
Expired before or around the early 2020s, depending on listed patent and term adjustments |
Removed the principal patent barrier |
| Generic approvals and launch |
Early 2020s |
Initiated direct price competition |
The principal listed patent associated with vorinostat has been identified in public patent databases as U.S. Patent No. 6,495,716. The patent was subject to patent-term adjustments or extensions reflected in public patent records, placing effective protection later than the ordinary 20-year term calculated from the earliest filing date [2, 4]. The commercially relevant point is that the patent estate no longer supports branded exclusivity.
What patents protect vorinostat?
The historical patent estate centered on the vorinostat chemical entity and related hydroxamic-acid compounds. The most commercially important U.S. patent was:
| Patent |
Subject matter |
Historical relevance |
| U.S. Patent No. 6,495,716 |
Substituted benzamide compounds, including vorinostat-related chemical matter |
Principal composition-of-matter protection |
| Related foreign filings |
Compound and pharmaceutical-use claims |
Country-specific historical protection |
| Formulation and use claims |
Dosing or therapeutic applications |
Limited strategic value after core compound expiry |
The strongest patent protection was the composition-of-matter claim set. Method-of-use patents had less economic value because the core CTCL indication was already covered by orphan exclusivity and the market is relatively small. Formulation protection has not created a durable barrier comparable to the original chemical patent.
Are there Paragraph IV challenges to vorinostat?
Vorinostat has reached the generic phase of its life cycle, but the public commercial record does not establish a continuing, material Paragraph IV dispute comparable to major branded oncology products. ANDA applicants could use Paragraph IV certifications against listed patents before those patents expired, but the key economic event was the end of the underlying patent and regulatory exclusivity periods.
For generic applicants, the risk profile was relatively manageable because:
- The product is an oral capsule with a conventional formulation.
- The active ingredient is chemically defined.
- The approved label is narrow.
- The principal patent estate is no longer in force.
- No biologic manufacturing complexity applies.
- The market can be entered through an ANDA rather than a 505(b)(2) application.
A Paragraph IV challenge would have mattered during the remaining patent term. It has limited current strategic importance unless a new, enforceable formulation or use patent is asserted.
What formulations are protected by vorinostat patents?
The commercial product is a 100 mg oral capsule. Vorinostat does not depend on a complex delivery system, controlled-release platform, device, or specialized formulation process.
This limits manufacturing and intellectual-property barriers. Generic manufacturers generally need to demonstrate pharmaceutical equivalence and bioequivalence to the reference product. The main technical requirements relate to:
- Capsule composition.
- Assay and impurity control.
- Dissolution performance.
- Stability.
- Manufacturing consistency.
- Bioequivalence.
- Compliance with current good manufacturing practices.
There is no major publicly established formulation patent protecting a differentiated extended-release or targeted-delivery version of vorinostat. The lack of formulation complexity increases the likelihood of multiple generic suppliers once demand is sufficient to support commercial entry.
How has the financial trajectory of vorinostat changed?
Vorinostat followed the typical trajectory of an orphan oncology drug: early branded growth, a limited revenue ceiling caused by a narrow patient population, and sharp post-exclusivity erosion.
Merck’s public filings reported Zolinza within oncology or related product categories, but the company did not consistently disclose a complete, standalone annual revenue series for the product. This limits precise year-by-year revenue reconstruction from SEC filings. Public reporting indicates that Zolinza was a modest product relative to Merck’s largest oncology and primary-care franchises [5, 6].
Branded growth phase
After the 2006 approval, revenue benefited from:
- Orphan-drug status.
- Limited approved systemic options for CTCL.
- Chronic treatment use in patients with persistent or recurrent disease.
- Specialist prescribing in dermatology and hematologic oncology.
- High branded oncology pricing relative to manufacturing cost.
The market remained limited because CTCL is a rare disease and the approved label required prior systemic therapy. Treatment duration and discontinuation were also affected by thrombocytopenia, anemia, fatigue, gastrointestinal toxicity, and creatinine or electrolyte abnormalities.
Mature branded phase
During the mature branded period, vorinostat faced competition from:
- Romidepsin, another HDAC inhibitor.
- Bexarotene.
- Denileukin diftitox, when commercially available.
- Brentuximab vedotin for CD30-positive disease.
- Mogamulizumab for relapsed or refractory CTCL.
- Skin-directed therapies and radiation.
- Chemotherapy and other systemic regimens.
The availability of therapies with different mechanisms reduced vorinostat’s ability to expand beyond its established niche. Physicians could select treatment based on CD30 expression, CCR4 expression, disease distribution, prior exposure, toxicity, and treatment setting.
Generic erosion phase
Once generic vorinostat entered the market, the product’s financial profile changed:
- Net price declined.
- Payer substitution increased.
- Specialty-pharmacy leverage weakened.
- Brand marketing became less economic.
- Revenue shifted toward generic volume and supply reliability.
- Manufacturer profitability depended on manufacturing cost and contract volume.
For a mature generic oncology capsule, the market can support several suppliers but may not support sustained high margins. Shortages, manufacturing interruptions, or limited supplier participation can temporarily increase prices, but those events do not recreate branded exclusivity.
How does vorinostat compare with competing CTCL drugs?
Vorinostat’s commercial position is determined by efficacy, tolerability, route of administration, biomarker relevance, and price.
| Drug |
Class |
Main commercial distinction |
Competitive effect on vorinostat |
| Vorinostat |
HDAC inhibitor |
Oral, generic, broad CTCL use after prior systemic therapy |
Low-cost systemic option |
| Romidepsin |
HDAC inhibitor |
Intravenous administration; similar mechanistic class |
Competes on response and physician preference |
| Bexarotene |
Retinoid X receptor agonist |
Oral treatment with lipid and thyroid monitoring |
Alternative systemic therapy |
| Brentuximab vedotin |
Antibody-drug conjugate |
Relevant for CD30-positive disease |
Captures biomarker-defined patients |
| Mogamulizumab |
Anti-CCR4 antibody |
Relevant in relapsed or refractory CTCL |
Strong competitor in eligible patients |
| Mechlorethamine gel |
Topical alkylating agent |
Skin-directed treatment |
Competes in cutaneous disease |
| Radiation therapy |
Local treatment |
High local response potential |
Reduces systemic-treatment need in selected patients |
Vorinostat retains advantages in oral administration, established clinical experience, and generic pricing. It is weaker where a patient has a biomarker-supported option, requires rapid disease control, or cannot tolerate the drug’s gastrointestinal, hematologic, or metabolic adverse effects.
What patent litigation affects vorinostat?
No major continuing U.S. patent litigation involving Zolinza is established in the cited public record as a current market driver. The commercially significant legal issues were the historical validity, scope, and expiration of the core compound patent and the timing of generic ANDA approvals.
Litigation risk is now more likely to arise from:
- Product liability claims.
- Manufacturing-quality disputes.
- Supply agreements.
- Antitrust or generic contracting matters.
- Labeling or pharmacovigilance issues.
- Attempts to assert later-filed formulation or method-of-use patents.
A new patent would need enforceable claims that materially distinguish the approved generic product. Such claims would face practical limits because the basic chemical entity and established CTCL use are no longer exclusive.
Which companies are challenging or competing with Zolinza?
The competitive field includes both generic vorinostat suppliers and branded companies selling alternative CTCL therapies.
Generic competition is expected from ANDA holders such as Teva and other approved or prospective manufacturers, subject to FDA approval status, market participation, and supply conditions. The most important competitive distinction is not the identity of one challenger but the number of suppliers willing to maintain inventory in a small oncology market.
Branded competitors include:
- Bristol Myers Squibb, through romidepsin-related commercial exposure.
- Kyowa Kirin, through mogamulizumab.
- Seagen and related commercial interests, through brentuximab vedotin.
- Manufacturers of bexarotene and topical CTCL therapies.
Generic competition can reduce the price of vorinostat without eliminating demand. CTCL treatment is recurrent and individualized, so clinicians may continue using vorinostat when its oral route, prior experience, or cost profile is favorable.
What generic entry risks exist for vorinostat?
The main generic-entry risk is price compression rather than an abrupt loss of all volume.
| Risk |
Expected impact |
| Multiple ANDA suppliers |
Lower acquisition price and weaker brand retention |
| Narrow market size |
Limits supplier participation and may create intermittent shortages |
| Low clinical differentiation |
Makes payer substitution easier |
| Competing branded therapies |
Restricts volume growth |
| Manufacturing complexity |
Low to moderate |
| Regulatory barrier |
Lower than for biologics or complex injectables |
| Reimbursement pressure |
High after generic entry |
| Brand residual demand |
Possible in continuity-of-care or supply-constrained settings |
The drug’s rarity can produce a paradox: generic competition is technically easy, but the market may be too small to attract many durable suppliers. That can preserve some value for reliable manufacturers while still reducing the originator’s revenue.
How strong is the vorinostat patent estate?
The historical patent estate was strong during the protected period because the key claims covered the active chemical entity. Current strength is low from a market-exclusivity perspective.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Historically strong; expired |
| Orphan exclusivity |
Expired |
| Formulation protection |
Limited commercial significance |
| Method-of-use protection |
Narrow and largely exhausted |
| Manufacturing know-how |
Moderate operational value, limited exclusionary value |
| Geographic coverage |
Historically broader in major markets; current value varies by country |
| Freedom-to-operate risk |
Generally manageable for standard generic capsules |
| Ability to block generic entry |
Low |
The remaining strategic value lies in manufacturing quality, supply reliability, regulatory execution, and distribution rather than exclusionary patent rights.
What is the commercial outlook for vorinostat?
Vorinostat is a mature, low-growth oncology product. Its future value depends on generic market structure, patient persistence, and competitive use in later-line CTCL.
The most likely commercial trajectory is:
- Continued decline in branded revenue after generic entry.
- Generic volume retention in cost-sensitive formularies.
- Stable but limited demand from CTCL specialists.
- Price competition among ANDA suppliers.
- Periodic supply volatility because of the small market.
- No material return to monopoly pricing without a new protected formulation or indication.
Expansion into unapproved cancers would require new clinical evidence, regulatory approval, and potentially new intellectual property. Earlier studies in multiple myeloma, leukemia, and solid tumors did not create a commercially durable second indication for the originator product.
Key Takeaways
- Vorinostat is an oral HDAC inhibitor approved for CTCL after two systemic therapies.
- Zolinza’s FDA approval was granted on Oct. 6, 2006.
- New chemical entity and orphan-drug exclusivity have expired.
- The core compound patent estate no longer provides a material U.S. barrier to generic entry.
- The product has no biosimilar risk because it is a small molecule.
- Generic competition is the principal source of current price and revenue pressure.
- Merck’s public filings do not provide a consistent standalone annual revenue series for Zolinza.
- The drug remains clinically relevant because it is oral, familiar to specialists, and available at generic pricing.
- Commercial upside is limited by CTCL’s small patient population and competition from romidepsin, mogamulizumab, brentuximab vedotin, bexarotene, and skin-directed treatments.
- The strongest remaining business advantages are manufacturing reliability, regulatory compliance, and supply continuity rather than patents.
FAQs
Is vorinostat still commercially available in the United States?
Yes. Vorinostat is available as the branded product Zolinza and as generic vorinostat capsules, subject to manufacturer supply and pharmacy distribution.
Is vorinostat a biologic drug?
No. Vorinostat is a chemically synthesized small-molecule drug. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.
What is the main indication for generic vorinostat?
The principal U.S. indication is progressive, persistent, or recurrent CTCL in patients who have received two systemic therapies.
Does vorinostat have meaningful remaining patent protection?
No meaningful broad patent barrier remains for the standard 100 mg oral capsule. Any later patent claims would need to cover a distinct formulation, manufacturing process, or method of use.
Why might vorinostat prices remain volatile after patent expiry?
CTCL is a small market. If only a few manufacturers maintain supply, production interruptions or inventory shortages can cause temporary price increases even after generic entry.
References
- U.S. Food and Drug Administration. (2006). Zolinza (vorinostat) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- U.S. Food and Drug Administration. (n.d.). Orphan drug designations and approvals database. https://www.accessdata.fda.gov/scripts/op relda/
- United States Patent and Trademark Office. (n.d.). Patent Center and patent term information for U.S. Patent No. 6,495,716. https://patentcenter.uspto.gov
- Merck & Co., Inc. (2007). 2006 annual report. Merck & Co., Inc.
- Merck & Co., Inc. (2013). 2012 annual report. Merck & Co., Inc.
